Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.70 |
| ▸ | CNR2 | P34972 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | PTGES | O14684 | 1/20 | 0.69 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150555 | 1.00 | PTGS2 (0.74) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL11405394 | 0.91 | PTGS2 (0.74) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL2739339 | 0.91 | PTGS2 (0.73) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL13408625 | 0.90 | PTGS2 (0.74) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL13390941 | 0.90 | PTGS2 (0.71) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| Tolmetin SCHEMBL8702881 | 0.87 | PTGS2 (0.59) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL11159263 | 0.87 | PTGS2 (0.80) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL29373123 | 0.86 | PTGS2 (0.80) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL11614146 | 0.86 | PTGS2 (0.83) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL29416586 | 0.86 | PTGS2 (0.79) | PTGS2PTGS1GLO1HIF1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1871 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | claimed |
| CN-118512401-A | Lipid vesicle compositions with permeation enhancers | 迪迪艾斯研究公司 | 2024-08-20 | — | — | CN | claimed |
| CN-115175667-B | Lipid vesicle compositions with permeation enhancers | 迪迪艾斯研究公司 | 2024-06-04 | — | — | CN | claimed |
| US-20240041935-A1 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-02-08 | — | — | US | claimed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | claimed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | claimed |
| CN-115175667-A | Lipid vesicle composition with permeation enhancer | 迪迪艾斯研究公司 | 2022-10-11 | — | — | CN | claimed |
| EP-4034087-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS Research Inc. (CA) | 2022-08-03 | — | — | EP | claimed |
| US-20220218611-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2022-07-14 | — | — | US | claimed |
| EP-3998932-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | Parsons, C. Lowell (US) | 2022-05-25 | — | — | EP | claimed |
| US-20020106345-A1 | Therapeutic compositions and methods | POLYMERIX CORPORATION | 2002-08-08 | — | — | US | claimed |
| WO-2002053188-A1 | COMPOSITIONS COMPRISING CYCLODEXTRINS AND NO-RELEASING DRUGS | NICOX S.A. (FR) | 2002-07-11 | — | — | WO | claimed |
| EP-1219306-A1 | Compositions comprising cyclodextrins and NO- releasing drugs | NICOX S.A. (FR) | 2002-07-03 | — | — | EP | claimed |
| EP-1192129-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-04-03 | — | — | EP | claimed |
| EP-1169298-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| WO-2001041753-A2 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING PERIODONTITIS WITH ANTIINFLAMATORY COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2001-06-14 | — | — | WO | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020106345-A1 | Therapeutic compositions and methods | COL2A1, BMP2, BMP4 | PTGS2 49/4885PTGS1 22/4885GLO1 2297/4885 |
| US-20220218611-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | PTGS2 2131/4885PTGS1 1749/4885GLO1 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.